June 25, 2015
Galena presented Phase 2 data on Gale-401: PHASE 2 STUDY OF A NOVEL CONTROLLED-RELEASE FORMULATION OF ANAGRELIDE (GALE-401) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-RELATED THROMBOCYTOSIS
Prof. Dr. Heinz Gisslinger presented a poster on CALR and ASXL1 mutations: IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY MYELOFIBROSIS STRICTLY DIAGNOSED ACCORDING TO THE WHO-CLASSIFICATION
Srdan Verstovsek presented an analysis of the Response Trial, which is studying Ruxolitinib: EFFECT OF RUXOLITINIB ON MARKERS OF IRON DEFICIENCY: AN ANALYSIS OF THE RESPONSE TRIAL
A poster presentation on NS Pharma’s compound NS-018 presented data on their Phase 1/2 trial which cited spleen reduction, hemoglobin improvement and platelet reduction: PHASE 1/2, DOSE-ESCALATION STUDY OF ORAL NS-018 IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF)
